CSR boundaries in the pharmaceutical industry: Is outsourcing of clinical trials to developing countries really unethical? by Gaidos, Alexandra Theodora
Journal of 
European Management 
& Public Affairs Studies 
 
2013 – Vol. 1 No. 1 
jempas.th-wildau.de 
 
Articles / Aufsätze 
 
CSR boundaries in the pharmaceutical  
industry: Is outsourcing of clinical trials to  
developing countries really unethical? 
Alexandra Theodora Gaidos  
Université des Sciences et Technologies de Lille (Lille I)  
Abstract. Does life have a different price according to the coun-
try where people are born? Should there be a customized defini-
tion of ethics in function of the country where clinical trials are 
being carried on? The actual international regulatory environ-
ment proves to be inadequate to guarantee a fair treatment of 
patients involved in drug trials around the world, a situation 
which is proven by the case of India. The incapacity of Indian 
national regulators to efficiently monitor trials and enforce the 
law, as well as the increasing use of outsourcing in clinical trials 
gives place to abuse of patients’ rights in the name of science or 
for corporate profits. The article aspires to make a modest con-
tribution to this field by analyzing to what extent pharmaceutical 
companies are interested in perpetuating the diffuse area around 
the responsibility and ethics of drug trials in developing coun-
tries. Moreover, it offers suggestions as to how they can improve 
their CSR practices.  
 
Keywords: bioethics, clinical trials, contract research organiza-
tions, drug trials, ethics, outsourcing, pharmaceutical industry 
 
Author: Alexandra Gaidos holds Master's degrees in Manage-
ment of European Affairs from the Université des Sciences et 
Technologies de Lille (Lille I) and in European Management 
from Technical University of Applied Sciences Wildau, Germa-
ny. A Romanian national, she completed her undergraduate 
degree at Bucharest Academy of Economic Studies in interna-
tional business and economics. She has worked as a research 
assistant with a pharmaceutical company and is currently an 
intern with Interreg IVB North-West Europe in Lille, France. 
Introduction 
Probably more than any other industry, the pharmaceutical in-
dustry is confronting itself with the ethical dilemma of striking a 
balance between corporate profitability, on the one hand, and its 
“ethical mandate” (Nussbaum, 2008) to provide access to treat-
ment for patients, on the other hand. Due to this fact, it has been 
the target for criticism of many NGOs (Non-governmental organ-
izations), journalists and consumer advocacy groups for issues 
such as pricing of medication, access to healthcare, protection of 
new discovered drugs by intellectual property rights and drug 
testing. 
In order to reestablish their reputation and to ensure their ac-
cess to markets, pharmaceutical companies have shown their 
motivation to become more socially responsible and begun to 
involve themselves in communities’ problems by reducing the 
price of their medication to disadvantaged groups, relaxing their 
property rights and participating in training or awareness cam-
paigns. However, ethical concerns around drug trials performed 
in developing countries such as India remain full of tensions. 
Responses given by pharmaceutical companies fail to show their 
commitment to apply a global standard of patient treatment 
involved in trials around the world.  
Moreover, increased competition and the strengthening of reg-
ulations in Western industrialized countries have pushed phar-
maceutical companies to change their business model and out-
source clinical trials to developing countries, transforming the 
drug research market into a rapidly globalized one (Abodor, 
2012). 
Inspired by the case of India, this paper aims at pointing out 
some of the flaws that exist in the regulatory environment of 
medical research, both in the case of developed countries (US 
and European) and of India. Furthermore, it develops on the 
resulting consequences that these flaws have on the behavior of 
the actors involved (pharmaceutical companies, contract research 
organizations, ethics committees and individual researchers and 
doctors). The final goal of this analysis will be to provide some 
recommendations for the pharmaceutical companies as to how to 
improve their transparency in medical research and avoid future 
unethical allegations. 
The regulatory environment 
Global rules: the Helsinki Declaration 
The supranational regime that sets universal principles in hu-
man research and consequently in clinical trials is represented by 
the Helsinki Declaration. This Declaration was inspired by the 
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Nuremberg Code and was first published in 1964 by the World 
Medical Association. In its current fifth revised edition, made in 
October 2000, it “puts patient safeguard before the advancement 
of science” (Abodor, 2012, p. 241) by introducing: a) the prima-
cy of the informed consent of patients,  b) ethics committees in 
charge with the supervision of the protocols of trials, c) the ban 
of ineffective placebos, d) the standards of conducting clinical 
trials and e) the definition of responsibilities between the parties 
involved in the management of clinical research. Moreover, since 
2000, when it emphasizes the duty of doctors towards the pa-
tients involved in the trials and their right to profit from the 
results of the study, by having access to the treatment discovered, 
the Declaration takes the form of a “modern Hippocratic oath” 
(Abodor, 2012). 
The importance of the Helsinki Declaration is crucial since it 
serves as a basis for the creation of national regulatory regimes. 
However, despite the clear ethical rules of conduct that it intro-
duces, its main weaknesses are the voluntary character of the 
guidelines and the lack of mechanisms to monitor and sanction 
abuses (Abodor, 2012, p. 246).  
Therefore, it falls in the responsibility of national institutions 
to shape their own policies in medical research and to allocate 
the resources needed, situation which creates the premises for 
large differences in the interpretation of the international regula-
tion, as well as in the efficiency of national regimes. 
US and EU standpoints on regulation of clinical trials 
The US and the EU are the two largest pharmaceutical mar-
kets, thus pushing the drug companies to pay extreme attention to 
comply with the regulations they pass. It is believed that the 
tightening of regulations in US and EU has triggered “a trend of 
offshoring” to developing countries the high risk clinical trials 
that would not be allowed by the American or European ethics 
committees (Politzer & Krishnan, 2012).  
If in 1962, when the US Food and Drug Administration (FDA) 
promulgated the first regulation on drug testing, the results from 
foreign trials were not easily accepted, the situation has com-
pletely changed at present. Nowadays, nearly 80 percent of drug 
applications for marketing approval use data obtained from 
foreign clinical trials and in some cases drug applications are 
approved entirely on foreign data (Schuman, 2012, p. 2). Ameri-
can policies tend to concentrate more on assuring the transparen-
cy of clinical trials, than on their ethical-related aspects. 
Examples are the National Institutes of Health (NIH) Data 
Sharing Policy, or the Annals of Internal Medicine policy, which 
publish data on study protocols, statistical codes and datasets. 
Moreover, the NIH manages the ClinicalTrials.gov site since 
2000, which is the largest single registry of clinical trials (Zarin 
& Tse, 2008, p. 1). To increase the number of trial registrations 
of all types of interventions around the world, the International 
Committee of Medical Journal Editors (ICMJE) has introduced 
in 2005 a policy that requires “prospective trial registration as a 
pre-condition for publication” (Zarin & Tse, 2008, p. 2). The 
latest improvement is the 2007 FDA Amendments Act 
(FDAAA). Section 801 of the FDAAA provides the first federal-
ly-funded trial results database and enlarges the scope of spon-
sors type and information that needs to be disclosed. However, 
the FDAAA 801 still leaves areas of opacity because it does not 
cover any issue related to the ethical conduct or design of clinical 
trials. Moreover, the FDA does not use injunctions or criminal 
proceedings to enforce its informed consent requirement abroad 
(Schuman, 2012).  
Consequently, its sole way to react to the deployment of uneth-
ical trials in the developing countries is to reject data coming 
from foreign research. However, since this measure occurs only 
ex post it does not offer any protection to the victims of clinical 
trials. According to Arthur Caplan, a bioethicist at the New York 
University Langone Medical Center, the main problem in pre-
venting unethical trials abroad is the absence of an international 
database of initiated trials. Consequently, the FDA is aware of a 
trial only when the drug companies submit the application to 
market the new drug: “We don’t have good information about 
what is really going on there, until there is a scandal, a problem 
or a death—but the overall picture is tough to know, because no 
one is responsible for monitoring it” (Politzer & Krishnan, 2012). 
The European pharmaceutical market is known to be one of 
the most regulated. Directive 2001/20/EC of 4 April 2001, in-
spired by the Declaration of Helsinki, sets standards for the 
conduct of clinical trials in the EU itself and explicitly requires 
that any application for market authorization in the EU needs to 
prove that the implied clinical trials, no matter in what country 
they were conducted, respect the same ethical standards applied 
to trials in the EU.  
However, according to a research by the Centre for Research 
on Multinational Corporations (SOMO), the provisions of the 
directive are not fully respected and the “European authorities 
devote little to no attention to the ethical aspects of the clinical 
trials submitted, and they accept unethical trials as well as trials 
of poor quality” (Schipper & Weyzig, 2008). For example, SO-
MO researchers identified a discrepancy between the require-
ments of the European Medicines Agency (EMA) which de-
mands placebo-controlled studies to grant market authorization 
and the ethical criteria of the Research Ethics Committees who 
do not approve this type of trial in most Western countries 
(Schipper & Weyzig, 2008, p. 70).  
Therefore, pharmaceutical companies are pushed to go to low 
or middle income countries where regulation is more lax. Both 
regulation systems, the American and the European one, have 
flaws in what concerns the ethical character of foreign research 
data, and it appears that one of the main causes is the lack of 
coordination between the legal measures and instruments applied 
by national medical regulators in developed and developing 
countries. 
Drug manufacturers between 
commitment to ethical trials and 
aggressive outsourcing 
The decision of pharmaceutical companies to outsource the 
stage of clinical trials to developing countries has been essential-
ly cost driven. The tightening of the regulation in the Western 
countries, the increasing R&D costs and time in recruiting pa-
tients to perform drug trials in developed countries (85 percent of 
days lost in clinical trials are due to a failure to get enough pa-
tients (McKinsey, 2009)) are factors that put pressure on their 
competitiveness. A special aspect not to be neglected is the time- 
and cost-intensive characteristic of the R&D process to discover 
and introduce a new drug on the market: approximately 10-15 
years, with an average cost per successful drug of $800 million to 
$1 billion. This amount includes also the cost of thousands of 
failures (IFPMA Clinical Trials Portal, 2013). Clinical trials 
expenses represent an important part in the cost break down, 
namely 60 percent of the drug development cost (Abodor, 2012).  
Compared to the US, India offers 30 percent time advantage in 
recruiting patients for trial, and cuts the cost per patient to half 
from approximately $4,000 - $10,000 in the US. Thus, in average 
it leads to savings of more than 50 percent for the three clinical 
trial phases (Veembur, 2004, p. 51).  
Nevertheless, the price components of medicines have been 
changing and in the case of the German pharmaceutical giant 
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Bayer for instance, it has been observed a different evolution of 
R&D costs compared to. According to their 2011 annual report, 
sales and advertising costs have outset the R&D costs by three 
times: in 2011, €8.96 billion were spent on advertising and €2.9 
billion on research (Bayer Annual Report, 2011). 
Emerging economies represent an economically rational 
choice for pharmaceutical companies to outsource phase II and 
III of the clinical trials (see Figure 1 below) and the reasons are 
manifold. On the one hand, there is the large number of popula-
tion, the variety of diseases and the fact that patients are some-
what “naïve” to modern treatment. On the other hand, regulation 
is more lax. This is the breach that raises the question of unethi-
cal treatment in clinical trials made in developing countries and 
because of which Big Pharma has come under criticiym. Moreo-
ver, attractiveness of outsourcing clinical trials to contract re-
search organizations (CROs) which allow drug companies to 
save time and money has its disadvantage of blurring the respon-
sibility of contractual parties in case of misconduct or deaths 
occurring because of the trial. 
 
 
Figure 1 – The process of drug discovery (IFPMA Clinical Trials 
Portal, 2013) 
 
Pushed by national regulators in US or EU to publish their tri-
als on publicly available sites and trial directories, the pharma-
ceutical companies are becoming more transparent. It has been 
shown, however, that without a legally constraint, they are not 
voluntarily disclosing information (Zarin & Tse, 2008).  
This type of opacity can become very harmful for the pharma-
ceutical industry and damage badly the confidence of their stake-
holders and patients. Citing the case of Bayer, in allegations of 
causing clinical trial-related death to more than a hundred of 
patients in India, shareholders have been demanding more trans-
parency from Bayer’s Board of managers. Finally, the savings 
that the companies realize by recurring to cheaper drug trials in 
developing countries can be several times overset by the losses in 
image and reputation due to unethical treatment of patients, 
recalls of medicines from the market and cost of lawsuits. 
If pharmaceutical companies do not take action in due time, 
consequences can be very dangerous for the industry in the long 
term. Already, in some cases, regulatory institutions in developed 
countries have refused to validate the results of trials conducted 
in outsourcing countries due to the uncertainty that the trials have 
respected the occidental standards. Moreover, because of differ-
ences in lifestyle and of the different exposure to drugs between 
Westerners and populations from developing countries, people 
can have different reactions to medicine and therefore, the regu-
lators might soon demand that the drug tests should be conducted 
on the people for which the drug is developed or that they per-
form a more balanced enrollment of patients around the world. 
As well as economically sound, the choice to contract a CRO 
gives the pharmaceutical companies the possibility to “out-
source” responsibility, or at least to harden the process of identi-
fying the culprits. However, this is not always in the benefit of 
the company. In some cases, the pharmaceutical companies have 
decided to cancel the outsourcing contract and continue doing 
trials in-house because of the high cost of monitoring the activity 
of the CRO (Politzer & Krishnan, 2012). 
India’s attractiveness 
India’s pharmaceutical market is believed to become the tenth 
largest market by 2015 attaining US$20 billion by 2015 
(McKinsey, 2009) (see figure 2), with its growth driven by a 
positive sustained economic evolution, an increase in healthcare 
spending, a reform of the healthcare system and an improvement 
in patent-related regulation. 
 
 
Figure 2 – Top pharmaceutical markets (IMS World Review) 
 
Starting from 2005 when the Indian government changed its 
patent law to recognize product patents and streamlined the 
process of clinical trials, India has become a very attractive 
market for pharmaceutical companies, transforming itself into a 
“Mecca of drug trials” (CRIN, 2012). This move was deliberate-
ly made by the Indian government to attract multinational corpo-
rations and foreign investments, arguing that their presence 
would on one hand benefit the economy, and on the other hand 
help better treat the Indian patients.  
This view is supported by the Indian Society for Clinical Re-
search (members of which are industry giants such as Bayer and 
Pfizer) who argues that it is in the best interest of India to pro-
vide an accommodating environment for pharmaceutical compa-
nies. This would favor the innovation process and prevent com-
panies from fleeing to other concurrent countries such as China, 
Vietnam or Philippines (Doherty, 2013).  
The Indian Society for Clinical Research suggests that India 
has a big potential for the drug trial and outsourcing industry due 
to its good infrastructure (more than 14,000 hospitals), the well 
trained doctors speaking English (more than half million practic-
ing doctors and over 200 accredited medical colleges) and the 
availability of “drug-naïve” patients with diverse genetic charac-
teristics and a good representation of Western diseases (Sinha, 
2012).  
However, the Indian regulatory framework is not adequate to 
the number and scale at which drug trials are conducted in the 
country. Despite the existence of appropriate laws, there is a 
considerable space for abuses due to the understaffed and un-
skilled ethical committees that have in charge the supervision of 
trials and protocols. The Central Drugs Standard Control Organi-
zation (CDSCO), which is the Indian governmental regulator, is 
in between keeping a flexible market for drug research, which 
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constitutes its main advantage, and applying a strict rule of law, 
which might be negatively perceived by the industry.  
The controversy around the number of clinical trial-related 
deaths and the notifications of abuses made by the National 
Human Rights Commission (NHRC) has pushed the Drug Con-
troller General of India (DCGI) to propose a further strengthen-
ing of the regulations. the deaths revealed by the CDSCO since 
2005 are estimated at 2644, of which 80 cases have been con-
firmed as having been caused by the drug that was tested and of 
which only 38 families have been compensated (Doherty, 2013).  
The provisions made under Schedule Y of the Drugs and Cos-
metics Rules concern providing financial compensation to trial 
subjects in case of trial related injury or death and stipulate the 
responsibilities of ethics committees, pharmaceutical companies 
and CROs (CBG, 2011). CROs are consequently made partly 
accountable for trial-related injuries and the sponsor company 
will have to market in the country the drug tested on Indian 
patients (Mathew, 2010).  
Despite the good intent to protect Indian patients, the practical 
method drafted by the CDSCO to calculate the amount of com-
pensations, is very controversial as it relies on the income of the 
injured or dead person along with age and severity of disease, 
transforming the poorest into a cheap target for investigators and 
leaving considerable place for subjectivism in the appreciation of 
the health condition of the patients (assessment made by the 
investigators themselves) (Nagarajan, 2012).  
The “format for obtaining informed consent of trial subjects is 
also proposed to be amended to include the details of address, 
occupation, annual income of the subject so as to have infor-
mation regarding socio-economic status of trial subjects” 
(Alexander, 2011). Another complementary proposal has also 
been made by the Drug Technical Advisory Board (DTAB) 
which stipulates that the investigators provide an audio/video 
recording of the informed consent of participants (Sinha, 2012). 
Because there is a large record of trials run without notice, the 
registration of clinical trials in the Clinical Trail Registry of the 
Indian Council of Medical Research has been mandatory.  
In conclusion, there is a clear commitment of the Indian gov-
ernment to further regulate medical research in the country, but 
the efficiency of the rules will be highly dependent on the human 
and financial resources that the government will deploy in order 
to enforce them and control the system. 
Current criticism of the practices in India 
Pharma companies and CROs who carry out drug trials in In-
dia are currently under serious allegations of unethical behavior. 
Criticism mainly deals with the ambiguity in proving the in-
formed consent of patients enrolled, the lack of transparency and 
the discriminatory treatment in terms of compensation for the 
patients who were injured or died as a result of the drug tested. 
The principle of informed consent is the fundamental corner-
stone of human medical research, set by the Declaration of Hel-
sinki and approved by all national regulators. However, there are 
serious concerns that this rule is not respected in the case of 
developing countries where most of the people enrolled in trials 
are poor, illiterate and in the case of India, belong to the deprived 
dalits, or the “untouchables” who are at the bottom of the Hindu 
caste system.  
Indian health organizations estimate around 350,000 to two 
million Indians involved in clinical trials and in some of the 
cases there is proof that the patients were not asked to sign a 
consent form and were not informed about being enrolled in drug 
trials. Sometimes the only information they were given was that 
they were offered “expensive new medicines free, paid for by a 
special governmental program for families living below poverty 
line” (Doherty, 2013). Moreover, when the death of patients 
occurred after they were discharged from hospital, as the families 
were not informed of previous involvement in drug trials, no 
“post mortem” investigations were made to establish the cause of 
the death. Since no evidence remained, the families were in the 
impossibility of asking for compensations. According to the 
figures reported to the DCGI, the number of drug trials and of 
clinical trial-related deaths has increased the latter evolving from 
137 in 2007 to 668 in 2010 (Shankar, 2011).  
Nevertheless, no compensations were made till the end of 2009 
and later, a total of 10 companies, including Bayer, Sanofi 
Aventis, Pfizer, Novartis and Eli Lilly, submitted a list of 22 
patients to whose families’ compensation was paid (five out of 
138 deaths in the case of Bayer and three out of 152 patients in 
the case of Sanofi Aventis) (Shankar, 2011). 
There is a fierce debate over the death causes of patients in-
volved in medical research because most of the people involved 
are in terminal stages or are suffering from some types of diseas-
es for which there is no discovered treatment yet. This is an 
argument that most of the pharmaceutical companies use to ex-
plain the small number of compensations.  
According to a Novartis spokesperson, “the clinical trial inves-
tigator (who conducted the trial for Novartis) had asserted the 
deaths were not because of the study medication but due to pro-
gression of underlying disease (which won’t necessitate compen-
sation)” (Mathew, 2011).  
However, even in the cases where compensations were made, 
sums paid were not comparable to similar cases in the US or 
Europe. Consequently, the pharmaceutical companies were ac-
cused of applying double standards in compensation. There are 
also opinions that due to the lax enforcement of law in India, the 
entire system is biased, thus favoring financial benefits over 
ethical concerns. According to C. M. Gulhati, editor of the 
Monthly Index of Medical Specialties:  
Many trials are taking place in private clinics of individual doctors 
whose sole motto is to make money. Can they be trusted to protect the 
interests of the subjects? Ethics Committees of private hospitals, where 
most trials are taking place, are appointed by owners and have hardly 
any powers to take decisions that can hurt their employers' income. 
Independent ethics committees are privately run and totally dependent 
on drug companies for their very survival. (Nagarajan, 2012) 
Even though pharmaceutical companies sustain that they re-
spect the international standards, their lack of transparency 
makes them very vulnerable to criticism. Moreover, by outsourc-
ing the clinical trials to CROs, they lack control over the methods 
used by the investigators. Even if on a contractual basis, the legal 
responsibility is transferred to CROs, there is no provision for the 
transfer of moral responsibility and therefore, there is a difficulty 
in assigning accountability when ethical malfeasance occurs 
(Abodor, 2012). When it occurs, the reputation of pharmaceutical 
companies is more affected than that of CROs, which are, unlike 
Big Pharma’s firm and brand names, mostly unknown to the 
public. It is a considerable risk. Yet the principle problem is 
India’s inadequate regulatory environment which permits the 
appearance of a “collusive nexus” between drug manufacturers, 
functionaries of the CDSCO and ethics committees, and medical 
practitioners (Doherty, 2013). 
Conclusions  
Despite recent improvements, the national regulatory frame-
works both in developed as in low and middle income countries 
lack the enforcement power to prevent further unethical clinical 
trials to be conducted, situation which emphasizes the increasing 
need of national medical regulators to cooperate and harmonize 
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their measures so as not to create an image of “cheap lives” of 
the people in developing countries. 
The case of India shows that there is a delicate balance be-
tween protection of commercial interests and promotion of public 
health. It is only through an ethical conduct of pharmaceutical 
companies, CROs and practitioners that both they and the Indian 
patients will benefit on the long term.  
Even if the lax enforcement of law in India considerably de-
creases the costs for pharmaceutical companies, the inexistence 
of a clear cut regulatory framework can have boomerang effects 
such as the rejection by US or EU authorities of research evi-
dence coming from Indian clinical trials due to allegations of 
unethical treatment or misappropriate and corrupt clinical proto-
cols.  
Moreover, the outsourcing of clinical trials to CROs can be 
double-edged for pharmaceutical companies because it exposes 
them to serious image loss in case of misconducts of the out-
sourcing company. 
One method for the pharmaceutical industry to maintain its 
credibility is by becoming more transparent and providing 
adapted information to medical specialists and to the general 
public concerning the number, location, protocol and results of 
conducted trials.  
Maintaining the obscurity of the current research system would 
only increase the suspicion of medical regulators that illegal or 
unethical practices are being used and would prevent potential 
patients from trusting the pharmaceutical companies and enrol-
ling into clinical trials. Furthermore, Big Pharma could and 
should use its negotiation power to impose ethical guidelines to 
its sub-contractors and local investigators to make all the re-
search chain more responsible.   
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